Market Research Reports

U.S. Vaccine Market (Human Vaccines: Hepatitis, Influenza, Meningococcal, Pneumococcal, HPV, Combination Vaccines; Animal Vaccines: Canine, Feline, Porcine, Bovine, Ovine, Poultry and Equine) - Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020

83pages
Published Date: 2015-01-27
 

Description



A vaccine is a biological preparation of killed forms of microbes, living attenuated organisms, living fully virulent organisms, a microbe’s toxins or one of its surface proteins. Vaccines play a key role in improving immunity against particular diseases. Therefore, vaccination is promoted as a vital public health intervention throughout the globe. According to the World Health Organization (WHO), vaccination has reduced the burden of infectious disease globally to a great extent. According to a study conducted by Zhou et al, vaccination prevented 42,000 early deaths and approximately 20 million cases of diseases in children born in the U.S. in 2009, resulting in saving USD 13.5 billion in direct medical and non-medical costs and USD 68.8 billion in total societal costs. 

This report on the U.S. vaccine market offers an insightful and in-depth assessment of the current as well as future market potential of human as well as animal vaccine markets. The human vaccine market is further segmented into pediatric and adult vaccine markets, based on vaccine type. On the basis of different antigens, the U.S. human vaccine market has been categorized into hepatitis, influenza, meningococcal, pneumococcal, human papillomavirus (HPV), combination vaccines and others. The U.S. animal vaccine market is broadly segmented as companion animal and livestock vaccine markets. The U.S. companion animal vaccine market segment has been further categorized into canine and feline, while the livestock vaccine market has been divided into porcine, bovine, ovine, poultry and equine markets.

Each of these segments and sub-segments has been extensively analyzed in the report, considering factors such as market trends, recent developments, future outlook and opportunities. The report provides market revenue size in terms of USD million for each segment and sub-segment for the period 2012 to 2020. In addition, the compounded annual growth rate (CAGR) of the overall U.S. vaccine market and various segments and sub-segments has also been provided in the report for the forecast period 2014 to 2020, considering 2012 and 2013 as the base years.

This report includes an elaborate executive summary, which covers a market snapshot representing key findings from the study on the U.S. vaccine market. The market overview section of the report on the U.S. vaccine market comprises qualitative analysis of the overall market considering factors determining market dynamics such as growth drivers, restraints and opportunities. The market overview chapter also includes a section describing the vaccine approval and regulatory pathway in the U.S. The competitive landscape section has been provided for both human and animal vaccine markets. This section presents the market revenue share of key players in terms of percentage for the year 2013. The market share analysis of key players involved the study of company product portfolio and sales revenue along with market developments such as new product launch and regulatory approvals.

This study on the U.S. vaccine market suggests a list of recommendations for new companies willing to enter the market and for existing companies to accentuate revenue shares, which is likely to help in the decision-making process. The report concludes with the profiles of major players in the U.S. vaccine market such as GlaxoSmithKline plc, Merck & Co., Inc., Novartis International AG, Pfizer, Ltd., Sanofi, Boehringer Ingelheim and Zoetis, Inc. Each company profile in the report contains information such as company overview, financial overview, product portfolio, business strategies and recent developments. The company overview section comprises basic information about the company such as major business areas, company’s brief history and its establishment year, number of employees and geographical presence. In the financial overview section, information such as selling and general administrative expenses, R&D expenses and annual revenue for the last three consecutive years (2011, 2012 and 2013) has been provided. The business strategies section mentions key strategies adopted by the company in the past to strengthen its position in the vaccine market. The recent development section gives information about the recent happening in the company related with the vaccine market.
 
The U.S. vaccine market is segmented as follows:

U.S. Human Vaccine Market, by Type
  • Pediatric
  • Adult
U.S. Human Vaccine Market, by Antigen
  • Hepatitis (A & B)
  • Influenza
  • Meningococcal
  • Pneumococcal
  • Human Papillomavirus (HPV)
  • Combination Vaccines (DTaP, DTaP-Hep B-IPV, DTaP-IPV and DTaP-IPV)
  • Others
U.S. Animal Vaccine Market, by Animal Type
  • Companion Animal Vaccine Market
    • Canine
    • Feline
  • Livestock Vaccine Market
    • Porcine
    • Bovine
    • Ovine
    • Poultry
    • Equine

Table of Contents



Chapter 1 Preface
1.1 Report Description
1.2 Market Segmentation
1.3 Research Methodology
      1.3.1 Assumptions
      1.3.2 Sources
              1.3.2.1 Secondary Research
              1.3.2.2 Primary Research
      1.3.3 Models

Chapter 2 Executive Summary
2.1 Market Snapshot: U.S. Vaccine Market (2013 & 2020)
2.2 U.S. Human Vaccine Market, by Antigen, 2013 (USD Million)

Chapter 3 U.S. Vaccine Market Overview
3.1 Introduction
3.2 Vaccine Approval Regulatory Pathway
      3.2.1 Major Steps: Vaccine Development and Commercialization
3.3 Drivers
      3.3.1 Growing incidence of zoonotic diseases drives increased animal vaccination
      3.3.2 Increasing consumption of chicken to augment the demand of poultry vaccines in the U.S.
      3.3.3 Extremely low risk of serious and fatal side effects associated with vaccines is a strong driver in the adoption of vaccines
      3.3.4 Education and awareness through various governmental and non-profit organizations
3.4 Restraints
      3.4.1 Strict regulatory pathway and high cost associated with new vaccine discovery and development
      3.4.2 High cost associated with vaccine transportation, storage and handling
3.5 Opportunities
      3.5.1 DNA vaccines hold immense potential for a number of human and animal diseases
      3.5.2 The U.S. offers immense potential for adult vaccines market
3.6 Competitive Landscape
      3.6.1 U.S. Human Vaccine Market Share Analysis, by Key Players, 2013 (Value %)
      3.6.2 U.S. Animal Vaccine Market Share Analysis, by Key Players, 2013 (Value %)

Chapter 4 U.S. Human Vaccine Market Revenue
4.1 Overview
      4.1.1 U.S. Human Vaccine Market Revenue, by Type, 2012 – 2020 (USD Million)
      4.1.2 U.S. Human Vaccine Market Revenue, by Antigen, 2012 – 2020 (USD Million)
      4.1.3 Comparative Analysis: U.S. Human Vaccine Market Revenue, by Antigen, 2013 & 2020 (Value %)
      4.1.4 Hepatitis
             4.1.4.1 U.S. Hepatitis Vaccine Market Revenue, 2012 – 2020 (USD Million)
      4.1.5 Influenza
              4.1.5.1 U.S. Influenza Vaccine Market Revenue, 2012 – 2020 (USD Million)
      4.1.6 Meningococcal
              4.1.6.1 U.S. Meningococcal Vaccine Market Revenue, 2012 – 2020 (USD Million)
      4.1.7 Pneumococcal
              4.1.7.1 U.S. Pneumococcal Vaccine Market Revenue, 2012 – 2020 (USD Million)
      4.1.8 Human Papillomavirus (HPV)
              4.1.8.1 U.S. Human Papillomavirus Vaccine Market Revenue, 2012 – 2020 (USD Million)
4.2 Combination Vaccines (DTaP, DTaP-Hep B-IPV, DTaP-IPV and DTaP-IPV)
      4.2.1 U.S. Combination Vaccine Market Revenue, 2012 – 2020 (USD Million)
      4.2.2 Others
             4.2.2.1 U.S. Other Vaccine Market Revenue, 2012 – 2020 (USD Million)

Chapter 5 U.S. Animal Vaccine Market Revenue, 2012 – 2020 (USD Million)
5.1 Overview
      5.1.1 U.S. Animal Vaccine Market Revenue, by Animal Type, 2012 – 2020 (USD Million)
      5.1.2 Comparative Analysis: U.S. Animal Vaccine Market Revenue, by Animal Type, 2013 & 2020 (Value %)
5.2 Companion Animal Vaccines
      5.2.1 U.S. Companion Animal Vaccine Market Revenue, by Segment, 2012 – 2020 (USD Million)
      5.2.2 Canine Vaccines
              5.2.2.1 U.S. Canine Vaccine Market Revenue, 2012 – 2020 (USD Million)
      5.2.3 Feline Vaccines
              5.2.3.1 U.S. Feline Vaccine Market Revenue, 2012 – 2020 (USD Million)
5.3 Livestock Vaccines
      5.3.1 U.S. Livestock Vaccine Market Revenue, by Segment, 2012 – 2020 (USD Million)
      5.3.2 Porcine Vaccines
              5.3.2.1 U.S. Porcine Vaccine Market Revenue, 2012 – 2020 (USD Million)
      5.3.3 Bovine Vaccines
              5.3.3.1 U.S. Bovine Vaccine Market Revenue, 2012 – 2020 (USD Million)
      5.3.4 Ovine Vaccines
              5.3.4.1 U.S. Ovine Vaccine Market Revenue, 2012 – 2020 (USD Million)
      5.3.5 Poultry Vaccines
              5.3.5.1 U.S. Poultry Vaccine Market Revenue, 2012 – 2020 (USD Million)
      5.3.6 Equine Vaccines
              5.3.6.1 U.S. Equine Vaccine Market Revenue, 2012 – 2020 (USD Million)

Chapter 6 Recommendations
6.1 Focus on cost-effective vaccine manufacturing
6.2 Focus on developing technologically advanced vaccines such as DNA vaccines

Chapter 7 Company Profiles
7.1 Boehringer Ingelheim
      7.1.1 Company Overview
      7.1.2 Financial Overview
      7.1.3 Product Portfolio
      7.1.4 Business Strategies
      7.1.5 Recent Developments
7.2 GlaxoSmithKline plc
      7.2.1 Company Overview
      7.2.2 Financial Overview
      7.2.3 Product Portfolio
      7.2.4 Business Strategies
      7.2.5 Recent Developments
7.3 Merck & Co., Inc.
      7.3.1 Company Overview
      7.3.2 Financial Overview
      7.3.3 Product Portfolio
      7.3.4 Business Strategies
      7.3.5 Recent Developments
7.4 Novartis International AG
      7.4.1 Company Overview
      7.4.2 Financial Overview
      7.4.3 Product Portfolio
      7.4.4 Business Strategies
      7.4.5 Recent Developments
7.5 Pfizer, Inc.
      7.5.1 Company Overview
      7.5.2 Financial Overview
      7.5.3 Product Portfolio
      7.5.4 Business Strategies
      7.5.5 Recent Developments
7.6 Sanofi SA
      7.6.1 Company Overview
      7.6.2 Financial Overview
      7.6.3 Product Portfolio
      7.6.4 Business Strategies
      7.6.5 Recent Developments
7.7 Zoetis, Inc.
      7.7.1 Company Overview
      7.7.2 Financial Overview
      7.7.3 Product Portfolio
      7.7.4 Business Strategies
      7.7.5 Recent Developments

List of Figures

FIG. 1 U.S. Vaccine: Market Segmentation
FIG. 2 U.S. Human Vaccine Market, by Antigen, 2013 (USD Million)
FIG. 3 Major Steps: Vaccine Development and Commercialization
FIG. 4 U.S. Human Vaccine Market Share Analysis, by Key Players, 2013 (Value %)
FIG. 5 U.S. Animal Vaccine Market Share Analysis, by Key Players, 2013 (Value %)
FIG. 6 Comparative Analysis: U.S. Human Vaccine Market Revenue, by Antigen, 2013 & 2020 (Value %)
FIG. 7 U.S. Hepatitis Vaccine Market Revenue, 2012 – 2020 (USD Million)
FIG. 8 U.S. Influenza Vaccine Market Revenue, 2012 – 2020 (USD Million)
FIG. 9 U.S. Meningococcal Vaccine Market Revenue, 2012 – 2020 (USD Million)
FIG. 10 U.S. Pneumococcal Vaccine Market Revenue, 2012 – 2020 (USD Million)
FIG. 11 U.S. Human Papillomavirus Vaccine Market Revenue, 2012 – 2020 (USD Million)
FIG. 12 U.S. Combination Vaccines Market Revenue, 2012 – 2020 (USD Million)
FIG. 13 U.S. Other Vaccine Market Revenue, 2012 – 2020 (USD Million)
FIG. 14 Comparative Analysis: U.S. Animal Vaccine Market Revenue, by Animal Type, 2013 & 2020 (Value %)
FIG. 15 U.S. Canine Vaccine Market Revenue, 2012 – 2020 (USD Million)
FIG. 16 U.S. Feline Vaccine Market Revenue, 2012 – 2020 (USD Million)
FIG. 17 U.S. Porcine Vaccine Market Revenue, 2012 – 2020 (USD Million)
FIG. 18 U.S. Bovine Vaccine Market Revenue, 2012 – 2020 (USD Million)
FIG. 19 U.S. Ovine Vaccine Market Revenue, 2012 – 2020 (USD Million)
FIG. 20 U.S. Poultry Vaccine Market Revenue, 2012 – 2020 (USD Million)
FIG. 21 U.S. Equine Vaccine Market Revenue, 2012 – 2020 (USD Million)
FIG. 22 Boehringer Ingelheim Vetmedica: Annual Revenue, by Segment, 2011 – 2013 (USD Million)
FIG. 23 GlaxoSmithKline plc: Annual Revenue, by Segment, 2011 – 2013 (USD Million)
FIG. 24 Merck & Co., Inc.: Annual Revenue, by Segment, 2011 – 2013 (USD Million)
FIG. 25 Novartis International AG: Annual Revenue, by Segment, 2011 – 2013 (USD Million)
FIG. 26 Pfizer, Inc.: Annual Revenue, by Segment, 2011 – 2013 (USD Million)
FIG. 27 Sanofi SA: Annual Revenue, by Segment, 2011 – 2013 (USD Million)
FIG. 28 Zoetis, Inc.: Annual Revenue, by Segment, 2011 – 2013 (USD Million)

List of Tables

TABLE 1 Market Snapshot: U.S. Vaccine Market (2013 & 2020)
TABLE 2 U.S. Human Vaccine Market Revenue, by Type, 2012 – 2020 (USD Million)
TABLE 3 U.S. Human Vaccine Market Revenue, by Antigen, 2012 – 2020 (USD Million)
TABLE 4 U.S. Animal Vaccine Market Revenue, by Animal Type, 2012 – 2020 (USD Million)
TABLE 5 U.S. Companion Animal Vaccine Market Revenue, by Segment, 2012 – 2020 (USD Million)
TABLE 6 U.S. Livestock Vaccine Market Revenue, by Segment, 2012 – 2020 (USD Million)
TABLE 7 Boehringer Ingelheim: Expenses & Revenue, 2011 – 2013 (USD Million)
TABLE 8 GlaxoSmithKline plc: Expenses & Revenue, 2011 – 2013 (USD Million)
TABLE 9 Merck & Co., Inc.: Expenses & Revenue, 2011 – 2013 (USD Million)
TABLE 10 Novartis International AG: Expenses & Revenue, 2011 – 2013 (USD Million)
TABLE 11 Pfizer, Inc.: Expenses & Revenue, 2011 – 2013 (USD Million)
TABLE 12 Sanofi SA: Expenses & Revenue, 2011 – 2013 (USD Million)
TABLE 13 Zoetis, Inc.: Expenses & Revenue, 2011 – 2013 (USD Million)

Enquiry Before Buying


Free Market Analysis


Over the past few years, the vaccine industry has established itself as one of the fastest-growing healthcare market segments. Vaccination has been of great help to public health. It has saved lives of millions of children, adults and animals, and provided them a better and healthier life. According to the Centers for Disease Control and Prevention (CDC), diseases such as diphtheria, smallpox and polio have been completely eradicated while diseases such as measles, rubella and tetanus have been better controlled in the U.S. Thus, vaccination is considered as the most effective form of all preventive measures.

The U.S. vaccine market is expected to expand at a CAGR of 4.3% during the forecast period between 2014 and 2020. The market has been broadly segmented into human and animal vaccines. The U.S. human vaccine market is expected to grow under the influence of factors such as low risk of serious and fatal side effects with vaccination, growing awareness regarding vaccination among common people as well as healthcare providers, federal government’s strict recommendations for immunization against certain diseases and growing demand for adult vaccines. On the other hand, the growth of the U.S. animal vaccine market is expected to be driven by the rising incidence of zoonotic diseases in animals and high risk of their transfer to humans, increasing pet ownership, and rising consumption of poultry meat, among other factors. Recently approved animal vaccines such as Prime Pac PRRS+ and Once PMH IN are also expected to drive the market growth in terms of revenue, primarily due to high prices associated with them.

On the other hand, stringent regulatory approval process and high cost associated with new vaccine discovery and development is expected to affect market growth during the forecast period. Transportation, storage and handling of vaccines are the major challenges faced by manufacturers and distributors. For more than 90% of all vaccines, manufacturers have to rely on cold chain logistics to prevent loss of potency and efficacy by exposure to temperatures outside the recommended range which results in high maintenance costs. Therefore, the high cost associated with transportation, storage and handling of vaccines is also expected to hamper growth of the vaccine market.

The human vaccine market is further segmented into pediatric and adult vaccines, based on vaccine type. However, on the basis of different antigens, the U.S. human vaccine market has been categorized into hepatitis, influenza, meningococcal, pneumococcal, human papillomavirus (HPV), combination vaccines and others. The combination vaccines market represented the largest segment of the human vaccine market in terms of revenue in 2013. The combination vaccines segment includes combination vaccines for diphtheria and tetanus along with other antigens such as pertussis, polio, hepatitis B, and Haemophilus influenza type B. The pneumococcal vaccines market is projected to emerge as the largest segment in 2020, primarily due to the expected strong increase in the sales of Prevnar 13 during the forecast period. The meningococcal vaccine market has been identified as the fastest growing segment during the forecast period. This is primarily due to the anticipated launch of pipeline products during the forecast period.

The animal vaccines market in the U.S. has been broadly classified as companion and livestock vaccines. The companion animal vaccines segment has been further categorized into canine and feline, while the livestock vaccines segment has been divided into porcine, bovine, ovine, poultry and equine sub-segments. The canine vaccines segment accounted for a slightly larger share (in terms of revenue) than the feline vaccines segment in 2013, due to higher average cost associated with canine vaccination. Of livestock vaccines, the bovine vaccine market accounted for the largest share in terms of revenue in 2013, followed by porcine. However, the poultry vaccines segment has been projected to grow at the highest CAGR during the forecast period from 2014 to 2020.

The U.S. human vaccine market is dominated by players such as GlaxoSmithKline plc, Sanofi, Pfizer, Ltd., Merck & Co., Inc., and Novartis International AG. These players compete with each other by introducing new and innovative vaccines. Zoetis, Inc., Merck & Co., Inc. (Merck Animal Health), Sanofi (Merial, animal health division of Sanofi) and Boehringer Ingelheim are the major companies in the U.S. animal vaccine market. Of these, Zoetis, Inc. was the largest stake holder in 2013, followed by Merck & Co., Inc. and Sanofi.

us-vaccine-market

 

To get discount on this report, just click on the button below.

To receive brochure, please click on the button below.

Share This Market Study!  

Upcoming Report

Payment
Copyright @ Transparency Market Research